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The basic helix-loop-helix (bHLH) transcription factor
OLIG2 is a master regulator of oligodendroglial
fate decisions and tumorigenic competence of gli-
oma stem-like cells (GSCs). However, the molecu-
lar mechanisms underlying dysregulation of OLIG2
function during gliomagenesis remains poorly under-
stood. Here, we show that OLIG2 modulates growth
factor signaling in two distinct populations of GSCs,
characterized by expression of either the epidermal
growth factor receptor (EGFR) or platelet-derived
growth factor receptor alpha (PDGFRa). Biochemical
analyses of OLIG2 function in normal and malignant
neural progenitors reveal a positive feedforward
loop betweenOLIG2 and EGFR to sustain co-expres-
sion. Furthermore, loss of OLIG2 function results in
mesenchymal transformation in PDGFRaHIGH GSCs,
a phenomenon that appears to be circumscribed in
EGFRHIGH GSCs. Exploitation of OLIG20s dual and
antithetical, pro-mitotic (EGFR-driven), and lineage-
specifying (PDGFRa-driven) functions by glioma
cells appears to be critical for sustaining growth
factor signaling and GSC molecular subtype.INTRODUCTION
Glioblastoma multiforme (GBM) is the most common primary
malignant brain tumor in adults, and despite profound molecular
and genetic analyses, patient outcome following standard-of-
care therapies remains dismal, with an average life expectancy
of 12–15months (Cloughesy et al., 2014). Intratumoral heteroge-
neity, diffuse infiltration throughout the brain parenchyma, and
resistance to traditional therapies pose a major clinical chal-
lenge, which inevitably leads to tumor recurrence and the demise
of the patient (Cloughesy et al., 2014). Recent work has high-
lighted the epigenetic and transcriptional networks of glioma
stem-like cells (GSCs) in human GBM (Suva` et al., 2014) and2838 Cell Reports 16, 2838–2845, September 13, 2016 ª 2016 The A
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mammalian brain (Alcantara Llaguno et al., 2015). Due to their
unique ability to self-renew and differentiate into the neuro-glial
lineages of the CNS, GSCs present a therapeutic burden by sus-
taining intratumoral heterogeneity and resistance to traditional
therapies (Lathia et al., 2015).
In the developing CNS, the balance between progenitor prolif-
eration and subtype specification is regulated by a diverse set
of proteins and extracellular cues. At the apex of this process
are transcription factors (TFs), such as the basic-helix-loop-helix
(bHLH) proteins, which harbor contradicting pro-neurogenic and
anti-neurogenic functions (Imayoshi and Kageyama, 2014a). The
dynamic expression of these proteins at various developmental
stages reflects their bi-functional nature—where constitutive
expression drives cell-cycle exit and differentiation, and oscilla-
tory expression sustains multipotency (Imayoshi and Kageyama,
2014b). During embryogenesis, the bHLH TF Olig2 is essential
for expansion of the progenitor pools and for specification of the
oligodendroglial lineage (Meijer et al., 2012). Universal expression
of OLIG2 in almost all cases of diffuse pediatric and adult glioma
suggests overlapping mechanisms between CNS development
and gliomagenesis (Ligon et al., 2004; Otero et al., 2011). In this
study, we set out to address the molecular mechanisms that
sustain OLIG2 expression and its pro-mitotic functions in cycling
neural progenitors. Cross-species investigative analysis sug-
gests that OLIG2 forms a positive feedforward loop with the re-
ceptor tyrosine kinases (RTKs) epidermal growth factor receptor
(EGFR) and the lineage-restricted platelet-derived growth factor
receptor alpha (PDGFRa). We describe an OLIG2-dependent
cell-autonomous nuclear mechanism for regulation of growth
factor signaling in normal and malignant neural progenitors.RESULTS
EGFR Signaling Sustains Olig2 Protein in Cycling Neural
Progenitors
To address the mechanisms that sustain Olig2 expression in
neural progenitors, we utilized the protein biosynthesis inhibitor
cycloheximide (CHX) to determine the half-life of Olig2 protein.
We observed a half-life between 4–8 hr for Olig2 protein in normaluthor(s).
creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. EGFR Signaling Regulates Olig2
Protein Turnover in Cycling Neural Pro-
genitors
(A) Murine neural progenitors were challenged with
cycloheximide (25 mg/ml CHX). Lysates were
collected at indicated time points and immuno-
blotted with antibodies directed against Olig2 and
Vinculin.
(B) Olig2 null cells expressing either phospho mu-
tants (TPN or TPM) were treated with CHX and
lysates were collected at indicated time points.
Immunoblotting was performed with antibodies
directed against Olig2 and Vinculin.
(C) Neural progenitors were treatedwith CHX alone
or in combination with EGFRi (10 mM erlotinib).
Immunoblotting was performed similarly to above.
Quantifications are shown on the right. Error bar
indicates mean ± SEM (nR 3). ****p < 0.0001.
See also Figure S1.(wild-type; p53/; Cdkn2a/) and malignant (Cdkn2a/;
EGFRvIII and p53/;EGFRvIII) neural progenitors, irrespective
of the genetic background (Figure 1A). Importantly, Olig2 levels
(mRNA and protein) were similar, with minimal deviation, across
selected genotypes (Figure S1A). When neural progenitors
were plated in factor-free media (i.e., depleted of exogenous
EGF/FGF2), phosphorylation of Olig2 at its amino-terminus
(Ser10,13,14) rapidly declined (Figure S1B) (Sun et al., 2011). We
observe no significant difference in the turnover time of either
triple-phospho-null (TPN; Ser to Ala) or triple-phospho-mimetic
(TPM; Ser to Glu/Asp) phospho mutant of Olig2 (Figure 1B).
Previous reports have implicatedmitogenic signaling as impor-
tant regulator of Olig2+ cells during CNS development and glio-
magenesis (Gonzalez-Perez et al., 2009; Persson et al., 2010).
To address the direct role of active EGF signaling in regulating
Olig2 protein expression, we utilized a known EGFR inhibitor, er-
lotinib (henceforth referred to as EGFRi). Treatment of neural pro-
genitors expressing Olig2 (Olig2/;mOlig2) with EGFRi in the
presence ofCHXover a 24-hr time course resulted in rapid deple-
tion of the Olig2 protein (T1/2 = 1 hr) (Figure 1C). Consistent with
this observation, treatment of murine neural progenitors with
EGFRi resulted in depletion of the Olig2 protein, irrespective of
the genetic background and phosphorylation status (Figures
S1CandS1D). Thesedata suggest that EGFR signalingmediates
the stability of Olig2 in neural progenitors and is independent of
amino-terminal phosphorylation and genetic background.
Phosphorylation of Olig2 Alters Expression of Growth
Factor Receptor Tyrosine Kinases
We and others have shown the Egfr is a direct genetic target
of Olig2 in neural progenitors in chromatin immunoprecipita-Cell Reportstion sequencing (ChIP-seq) and RNA
sequencing (RNA-seq) studies (Mateo
et al., 2015;Meijer et al., 2014). Qualitative
analysis of Olig2 binding sites reveals
its localization to intronic and distal
upstream regions of the Egfr loci, marked
by deposition of H3K4me1 and H3K27ac,indicating these sites as putative enhancers (Figure S2A). To vali-
date these ChIP-seq findings on whether Egfr is a direct genetic
target of Olig2, we analyzed Olig2 null neural progenitors ex-
pressing control GFP (knockout [KO]), wild-type (WT), TPN, or
TPM forms of murine Olig2. Immunoblot analysis suggests that
germline ablation (KO) or loss of amino-terminal phosphorylation
(TPN) of Olig2 reduces the expression of Egfr in normal (WT) and
malignant (Cdkn2a/;EGFRvIII) neural progenitors (Figure 2A).
We have previously shown that the phosphorylation state of
Olig2 alters the mRNA levels of various RTKs (Meijer et al.,
2014); however, these cell lines were engineered to express
either phospho mutant under a constitutive viral promoter
against an Olig2 null genetic background. We extend these
observations to knockin (KI) neural progenitors, wherein the
endogenous Olig2 locus was replaced with either the TPN or
TPM coding sequences (Olig2TPN/TPN, Olig2TPM/TPM). Consistent
with the overexpression system, we observed a significant upre-
gulation of the RTKs Egfr, Fgfr3, and Pdgfra mRNA and repres-
sion of the cell-cycle inhibitor Cdkn1a and astrocytic marker
Gfap mRNA in TPM- versus TPN-expressing cells (Figure S2B).
We have previously reported that Olig2 phosphorylation is
dispensable for progenitor proliferation and tumor initiation
when p53 is genetically inactivated. However, the rate of tumor
formation is significantly increased in the presence of Olig2
(i.e.,Olig2cre/+ versusOlig2cre/cre) in a murine model of malignant
glioma harboring deletion of the p53 locus (p53flox/flox;EGFRvIII)
(Mehta et al., 2011). To assess if Olig2-mediated regulation
of Egfr is dependent on the tumor suppressor protein p53, we
attenuated p53 function in phospho mutant KI cells. As shown
in Figure 2B, ectopic expression of dominant-negative p53
(p53DD) in neural progenitors expressing TPN mutant, was16, 2838–2845, September 13, 2016 2839
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Figure 2. Olig2 Regulates Expression of Egfr in Murine Neural Progenitors
(A) Olig2 null cells expressing control GFP, wild-type (WT), or phospho mutants (TPN or TPM) of Olig2 were assayed for Egfr and Olig2 protein levels. Quanti-
fications of Egfr (and EGFRvIII) protein levels are shown on the right (A’). Error bar indicates mean ± SEM (nR 3).
(B) Knockin neural progenitors expressing the TPN or TPM mutant of Olig2 (Olig2TPN/TPN and Olig2TPM/TPM) expressing either control GFP or dominant-negative
p53 (p53DD). Protein levels of Egfr, Olig2, and p53 were assayed as above.
(C) Comparison of intracranial xenografts derived frommurine glioma cells expressing TPN or TPMmutants of Olig2 (V5 tagged). Sections were stained with Egfr
(green) and V5 (red) antibody to visualize tumor cells. Scale bar, 100 mM.
(D) Olig2 null cells expressing control GFP, wild-type (WT), or FLAG/HA-tagged DNA binding mutant (D) of Olig2 were assayed for Egfr and Olig2 protein levels
(nR 3).
See also Figure S2.insufficient to induce Egfr expression suggesting that Olig2-
mediated regulation of Egfr is independent of p53 status.
To confirm phospho-dependent upregulation of Egfr in vivo,
we orthotopically transplanted murine glioma cells (Cdkn2a/;
EGFRvIII) expressing either of the Olig2 phospho mutants into
the brains of immunocompromised mice. This murine glioma
model recapitulates the hallmark genetic lesions of the ‘‘clas-
sical’’ GBM molecular subtype: constitutive EGFR signaling
(EGFRvIII), homozygous deletion of the Cdkn2a locus, and an
intact p53 gene (Verhaak et al., 2010). Olig2 function is required
to initiate tumors in this glioma model, and amino-terminal phos-
phorylation regulates its tumorigenic competence (Ligon et al.,
2007; Sun et al., 2011). Consistent with our in vitro findings,
we observed stronger immunoreactivity of Egfr protein in
TPM-expressing tumors compared to TPN-expressing tumors
(Figure 2C).
To confirm if Olig2 DNA-binding is required to promote
expression of Egfr, we analyzed Olig2 null cells expressing con-
trol GFP (KO), WT-Olig2, or a DNA-binding mutant (DOlig2) that
harbors a point mutation (N114H) in the basic region that abro-
gates canonical E-Box recognition (Meijer et al., 2014). As
seen in Figure 2D, germline ablation ofOlig2 or loss of DNA-bind-
ing function led to diminished expression of Egfr in wild-typemu-
rine neural progenitors. Finally, we tested whether DOlig2 can
antagonize endogenous Olig2 protein function. Ectopic expres-
sion of DOlig2 in malignant neural progenitors (Cdkn2a/;
EGFRvIII and p53/;EGFRvIII) led to substantial repression of2840 Cell Reports 16, 2838–2845, September 13, 2016Egfr protein levels (Figure S2C). These findings suggest that
Olig2 promotes Egfr expression through activity of the amino-
terminal phosphorylation motif in a DNA-binding-dependent
manner.
OLIG2 Regulates Expression of EGFR and PDGFRa in
hGSCs
To address whether the cross-regulatory loop between OLIG2
and RTKs persists in human GSCs (hGSCs), we isolated and en-
riched for neurosphere-forming cells from patient-derived GBM
tissues (Table S1). Immunoblot analysis showed that hGSCswith
higher levels of pOLIG2 shared expression of the EGFR (BT112,
BT286, GB82, BT145), with varying levels of the PDGFRa. In
contrast, pOLIG2 levels are largely diminished in EGFRLOW
(BT187, BT142, GB3, GB16, GB80) hGSCs, which often dis-
played high expression of PDGFRa, reminiscent of the proneural
GBM subtype (Figure 3A). To simplify the nomenclature, we have
termed hGSCs displaying EGFRHIGH expression as classical
(CLS) and EGFRLOW/PDGFRaHIGH expression as proneural
(PN). To confirm a role for active EGFR signaling in sustaining
OLIG2 protein in hGSCs (BT145, BT112), we treated the cells
with EGFRi + CHX and observed a rapid depletion of the
OLIG2 protein, compared to CHX alone (Figure S3A). These find-
ings suggest that, similar to murine neural progenitors, EGFR
signaling sustains the OLIG2 protein in CLS hGSCs.
The expression of OLIG2 protein in both PN and CLS hGSCs
led us to inquire if these developmentally regulated pro-neural
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Figure 3. OLIG2 Regulates Expression of RTKs in hGSCs
(A) Lysates derived from hGSCs were immunoblotted with antibodies to pOLIG2, OLIG2, EGFR, PDGFRa, and Vinculin.
(B) hGSCs (BT145, BT112, GB3, GB16) were transduced with shNT (non-target control) or shOLIG2. Lysates were collected 48 hr post-infection and
immunoblotted for EGFR, PDGFRa, OLIG2, and Vinculin.
(C) hGSCs expressing GFP or d Olig2 (FLAG tag), and the levels of EGFR and PDGFRa were assayed as above.
(D) hGSCs were transduced with retrovirus expressing GFP or WT-Olig2 (V5 tag), and the levels of EGFR and PDGFRa were assayed using standard immu-
noblotting techniques.
(E) Lysates from hGSCs expressing GFP or Olig2 phosphomutants (TPN and TPM) were collected to assay protein levels of EGFR and PDGFRa, ectopic (V5 tag),
and endogenous OLIG2 (nR 3). *Denotes 90 kDa EGFR band, uniquely expressed in GB16.
See also Figure S3.(lineage-specifying) and anti-neural (proliferative) functions of
OLIG2 were co-opted in hGSCs. After acute silencing of OLIG2
in both CLS (BT145 and BT112) and PN (GB3 and GB16) hGSCs,
we observed a significant downregulation of both RTKs, inde-
pendent of the molecular subtype (Figure 3B). We confirmed
specificity and effects of small hairpin RNA (shRNA)-mediated
knockdown by utilizing three alternate hairpins targeting the hu-
man OLIG2 ORF (Figure S3B). In contrast to recent findings (Lu
et al., 2016), we did not observe a parallel upregulation of
EGFR protein following acute silencing of OLIG2 in PDGFRaHIGH
hGSCs (Figures 3B and S3C). Furthermore, analysis of published
OLIG2/H3K27ac ChIP-seq data in hGSCs (Suva` et al., 2014)
confirms OLIG2 binding at both distal and intronic enhancers
at both the EGFR and PDGFRA loci (data not shown). We
also observed a significant downregulation of both RTK tran-
scripts (EGFR and PDGFRA) following acute OLIG2 silencing
(Figure S3D).
We next addressed whether DOlig2 can assert itself in a domi-
nant-negative manner in hGSCs. We assessed protein levels of
EGFR and PDGFRa from two CLS (BT145, BT112) and two PN
(GB3, GB16) lines where we have chronically overexpressed
DOlig2. We observed a substantial downregulation of the RTKs
in all hGSCs surveyed (Figures 3C and S3E), indicating an
OLIG2 loss-of-function phenotypemediated by the DNA-bindingmutant (D). qRT-PCR analysis confirmed the downregulation of
RTK transcripts (i.e., EGFR,PDGFRA) in presence ofDOlig2 (Fig-
ure S3F). To further confirmOLIG2-mediated regulation of RTKs,
we ectopically introduced wild-type Olig2 or control GFP into
either the BT145CLS or GB16PN hGSC line. Surprisingly, following
overexpression of WT-Olig2 we observed an induction of
PDGFRa protein in our CLS/EGFRHIGH line (BT145) and induc-
tion of EGFR protein in our PN/PDGFRaHIGH line (GB16) (Fig-
ure 3D). Finally, we asked if the phosphorylation status of
OLIG2 is critical for sustaining the expression of RTKs in human
GSCs. We utilized retroviral expression vectors to introduce
control GFP or the phospho mutants (TPN, TPM) in either the
BT145CLS or GB16PN hGSC lines. We observed a reduction in
the protein levels of both the EGFR and PDGFRa (albeit more
modest) protein following overexpression of TPN-Olig2, but not
TPM-Olig2 (Figure 3E). These data suggest that OLIG2 regulates
the expression of both the EGFR and PDGFRa in hGSCs.
OLIG2 Is the Nuclear Gateway for Proneural-
Mesenchymal Transition
Wenext askedwhether loss ofOLIG2 leads to a shift in GBMmo-
lecular subtype. To investigate the functional outcomes ofOLIG2
knockdown in hGSCs, we utilized shRNA to ablate the OLIG2
protein in both CLS/EGFRHIGH and PN/PDGFRaHIGH hGSCs.Cell Reports 16, 2838–2845, September 13, 2016 2841
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Figure 4. OLIG2 Is the Nuclear Gateway for Proneural-Mesenchymal Transition
(A) hGSCs (BT145, GB3) were transduced with shNT (non-target control) or shOLIG2. Lysates were collected 48 hr post-transduction and immunoblotted for the
indicated proteins.
(B and C) Lysates from hGSCs expressing control GFP, WT-Olig2 (V5 tag), or DOlig2 (FLAG tag) were collected and immunoblotted for CD44, GFAP, and ectopic
Olig2. Note: blots presented here were re-probed from Figures 3C and 3D.
(D) qRT-PCR analysis of hGSCs (BT145, GB16) expressing control GFP or DOlig2 for indicated subclass genes. HPRT and 18 s were utilized as housekeeping
genes. Error bar indicates mean ± SEM (nR 3).
(E) Proposed model of OLIG2-mediated regulation of growth factor signaling.
See also Figure S4.Weobserved a robust induction of the astrocytic marker GFAP in
our CLS lines (BT145, GB71, GB82), whereas the mesenchymal
marker CD44 is induced in PN lines (GB3, GB16, GB80) (Figures
4A and S4A). However, this ‘‘mutually exclusive’’ upregulation of
the GFAP and CD44 proteins does not fully extend to all hGSC
lines examined (e.g., GB71CLS): lines that express appreciable
GFAP protein prior to OLIG2 knockdown, appear to upregulate
both GFAP and CD44 (Figure S4A). Consistent with a loss of
‘‘stemness,’’ we observed a substantial downregulation of the
glioma master transcription factor SOX2 followingOLIG2 knock-
down in all CLS/PN lines examined (Figure S4A). These data sug-
gest that acute loss of OLIG2 collapses the ‘‘stem’’ state in
hGSCs, with a subsequent shift to a more differentiated state.
To further assess OLIG2-dependent regulation of GFAP and
CD44, we utilized hGSC lines (BT145CLS and GB16PN) to ectop-
ically express WT-Olig2 or the DNA-binding mutant DOlig2. We2842 Cell Reports 16, 2838–2845, September 13, 2016observed repression of both the CD44 and GFAP proteins in
lines where we have overexpressed WT-Olig2 (Figure 4B). In
striking contrast, chronic overexpression of dominant-negative
Olig2 (DOlig2) resulted in upregulation of the CD44 protein
(but not GFAP)—suggesting mesenchymal (but not astroglial)
conversion (Figure 4C). To assess if loss of OLIG2 function trig-
gers a proneural-mesenchymal transition (PMT), we performed
expression analysis for GBM molecular subtype-specific genes
in four independent hGSCs lines expressing DOlig2 (BT145,
BT112, GB3, GB16). We observed a catastrophic loss of proneu-
ral class genes and upregulation of mesenchymal class genes in
our DOlig2-expressing hGSCs compared to GFP-expressing
controls, independent of the original molecular subtype (i.e.,
CLS versus PN) (Figures 4D and S4B). Conversely, overexpres-
sion of WT-Olig2 results in upregulation of proneural class genes
and downregulation of mesenchymal class genes (Figure S4C).
We further extend these ‘‘PMT’’ expression shift observations to
murine glioma lines of defined genetic backgrounds (Cdkn2a/;
EGFRvIII and p53/;EGFRvIII) expressing DOlig2 (Figure S4D).
Thus, our data support a model in which OLIG2 serves as a crit-
ical mediator of growth factor signaling (i.e., RTK expression)
and GSC identity (Figure 4E).
DISCUSSION
A key determinant of intratumoral heterogeneity in malignant gli-
omas is likely to be glioma stem-like cells, which promote tumor
growth, recurrence, and therapeutic resistance (Lathia et al.,
2015). Identification of proteins that drive GSC biology is of
special interest in neuro-oncology. One such protein that is ex-
pressed in GSCs, glial-restricted progenitors and their respec-
tive progeny is the bHLH TF Olig2 (Ligon et al., 2007). During
the early stages of CNS development, Olig2 serves to prevent
premature cell-cycle exit in developmentally uncommitted neu-
ral progenitors, and at later time points, promote differentiation
into oligodendrocytes (Meijer et al., 2012). Previous work has
coupled the pro-mitotic functions of Olig2 to phosphorylation
of a cluster of serines at its amino-terminus (Ser10,13,14), also
known as the phospho-serine-motif. Mutation of this motif into
a ‘‘null’’ state (Ser to Ala) impedes neural progenitor proliferation
and the tumorigenic capacity of murine GSCs (Sun et al., 2011).
Further biochemical analyses of these mutants suggest little
to no alteration in genomic targeting, but rather a difference in in-
tranuclear localization and co-regulator association (Meijer et al.,
2014). Here, we investigated themechanisms that sustain OLIG2
expression and its proliferative functions in neural progenitors
and assessed whether these signals are co-opted in malignant
gliomas. We have identified an ‘‘OLIG2-RTK’’ signaling axis,
which functions in a feedforward manner to sustain co-expres-
sion. This loop appears to be conserved in both normal and
malignant neural progenitors, highlighting a previously unappre-
ciated relationship between OLIG2 and EGFR signaling (Aguirre
et al., 2007; Persson et al., 2010).
Constitutive growth factor signaling is a hallmark of diffuse
gliomas, propagated by activating genetic lesions in RTKs,
most commonly within the EGFR and PDGFRA locus (Verhaak
et al., 2010), which appear to be mutually exclusive oncogenic
events (Snuderl et al., 2011). Mutations at the EGFR locus occur
in the classical subtype and mutations in the PDGFRA locus
occur primarily in the proneural subtype (Verhaak et al., 2010).
While these two molecular subtypes appear similar on a histo-
pathological level, their expression profiles suggest that they
might have disparate cellular origins. Recent elegant mouse
modeling studies (Alcantara Llaguno et al., 2015) suggests that
both multipotent neural stem cells (NSCs) and lineage-restricted
oligodendrocyte precursor cells (OPCs) are capable of giving
rise to anatomically and molecularly unique types of GBM
when transformed with identical mutations (i.e., Tp53, Pten,
Nf1 deletion) using cell-specific Cre-drivers (NestincreER for
NSCs, Ascl1creER for NSC/OPCs, Cspg4creER for OPCs). These
authors observed expression of Olig2 in both type I (‘‘NSC’’-
like) and type II (‘‘OPC’’-like) tumors in their genetically engi-
neered mouse models. In our patient-derived GSCs, we observe
universal expression of OLIG2 and two distinct states of phos-phorylated OLIG2 (low versus high), which appear to correlate
with dominant expression of the RTKs EGFR or PDGFRa (CLS
versus PN) (Figure 3A). As the developmental functions of
Olig2 amino-terminal phosphorylation are presumably complete
following the formation of mature white matter—its presence in
PDGFRa-expressing (PN) hGSCs presents a paradox. Is the
phospho-serine-motif performing an identical function in these
hGSCs (compared to their CLS counterparts)? Our biochemical
analyses of OLIG2 function in both hGSC populations (CLS and
PN) suggest a requirement for intact phosphorylation to sustain
expression of the EGFR, while having only a modest impact on
PDGFRa expression (Figure 3E). This finding is consistent with
previous observations that indicated amino-terminal phosphory-
lation is not critically required for oligodendroglial lineage
specification (Sun et al., 2011). However, expression of both
RTKs is repressed upon introduction of a DNA-binding mutant
(DOlig2), which appears to function in a dominant-negative
manner (Figures 3C and 4D). This suggests that while phos-
pho-serine-motif functions might persist in PN hGSCs, the larger
pool of un-phosphorylated OLIG2 may be performing a second-
ary function.
We have previously reported that the pro-mitotic functions of
Olig2 indirectly promote radio-resistance through antagoniza-
tion of p53 transactivation (Mehta et al., 2011). Recent work
(Bhat et al., 2013; Carro et al., 2010) has proposed a phenome-
non termed ‘‘proneural-mesenchymal transition’’ as mediating
radio-resistance and aggressive recurrence in malignant gli-
omas. In this model of progressive resistance, glioma cells ac-
quire mesenchymal traits and lose proneural gene expression.
In this study, we attempted to reconcile these results through
cross-species investigative analysis of OLIG2molecular function
in normal and malignant neural progenitors. We observe that
CLS hGSCs resist mesenchymal transformation and shift toward
the astroglial lineage (i.e., GFAP versus CD44 upregulation)
following ablation of OLIG2. In contrast, PN hGSCs strongly
upregulate the CD44 protein (Figures 4A and S4A). Notably,
mesenchymal transformation does not appear to be entirely
exclusive to astrocytic differentiation, as we observe a parallel
upregulation of GFAP in some lines following OLIG2 loss (Fig-
ure S4A). This does not, however, exclude fate conversion—as
during development the CD44 protein has been shown to label
astroglial-restricted progenitors that do not yet express GFAP
(Liu et al., 2004; Gonzalez et al., 2014).
Thus, OLIG2 that is uniquely CNS-restricted among a quartet
of gliomamaster TFs (Suva` et al., 2014), appears to function as a
‘‘nuclear gateway’’ for proneural gene and RTK expression in
hGSCs (Figures 4D and 4E). Similar molecular subtype conver-
sion findings were recently presented (Lu et al., 2016), however,
these authors observed a ‘‘proneural-classical’’ subtype shift
following Olig2 deletion. These authors employed a murine gli-
oma model that initiates tumors in a very specific cell type (white
matter OPCs) bearingmutations unique to the proneural subtype
(Tp53;Pten deletion; Pdgfb overexpression), excluding the pos-
sibility of transformation in more naive cells (i.e., neural stem/
progenitor cells) and Olig2 functions therein (i.e., sustaining
Egfr expression; Figure 2). Similar to our findings, Lu et al.
(2016) also observed a global collapse of the proneural gene
expression program following chronic Olig2 deletion, consistentCell Reports 16, 2838–2845, September 13, 2016 2843
with a loss of OPC character. Unlike our observed PMT, these
authors observed an upregulation of the Egfr and classical sub-
type genes. However, it is important to note that the EGFR can
be expressed in a plethora of normal and neoplastic cells,
many of which do not express OLIG2 (e.g., astrocytes, immortal-
ized glioma cell lines) and lack cancer stem cell identity (Care´n
et al., 2015; Suva` et al., 2014). Thus, this observation by Lu
et al. (2016) of Egfr upregulation following chronic Olig2 deletion
is possibly a result of astroglial restriction (and dissimilar to our
acute silencing experiments). Importantly, a functional role for
Egfr in oligodendroglial lineage cells during CNS development
and gliomagenesis has been well documented (Aguirre et al.,
2007; Persson et al., 2010), and a role for Olig2 in repression of
the Egfr locus is difficult to reconcile with this pre-existing data
(as postulated in Lu et al., 2016). Consistent with our murine
data and unlike Lu et al. (2016) study, we observed a decrease
in EGFR protein after loss of OLIG2 function in hGSCs. It
is possible that differences in other genomic alterations apart
from PDGFRa amplifications also play a role in subtype
specification (Ozawa et al., 2014). Further analysis of the
micro-environmental cues and intracellular mediators of this
proliferation-differentiation (EGFR-PDGFRa) switch will provide
additional mechanistic insight into the process of subtype con-
version and may present novel therapies for patients with malig-
nant gliomas (Singh et al., 2016). We therein propose a model
where OLIG2 resides at the intersection of two cross regulatory
loops in normal and malignant neural progenitors, forming
a compulsory link between cell-cycle regulation and sub-type
specification, dictated through spatiotemporal protein modifica-
tions that promote self-renewal or fate choice.
EXPERIMENTAL PROCEDURES
Animal Procedures, Tissue Harvest, and Cell Culture
Animal husbandry was performed according to Barrow Neurological Institute
(BNI) guidelines under IACUC-approved protocols. Derivation and culture of
neural progenitor cell lines used have been described previously (Mehta
et al., 2011). Generation of murine Olig2 mutant constructs have been previ-
ously described (Meijer et al., 2014).
Immunoblotting and qRT-PCR
Immunoblottingwas performed using standard protocols previously described
(Meijer et al., 2014). A full list of antibodies used is provided in theSupplemental
Information. RNA and cDNA was prepared using previously described
methods (Meijer et al., 2014).
Statistical Analysis
For each experiment, data were collected from at least three biological repeats
and analyzed by one-way or two-way ANOVA with Bonferroni multiple com-
parisons test as indicated (*p < 0.05; **p < 0.01; ***p < 0.001).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
four figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2016.08.040.
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